One Medicine, One Payment: How Boehringer Ingelheim Is Closing the Loop on Site Payments
After consolidating 40 systems into one platform, Boehringer Ingelheim's Sarita Thomas explains why site payments was the missing piece...
The Study Build That Used to Take Weeks Now Takes Minutes
Inside Crucial Data Solutions' Floyd AI and the case for synthetic control arms
20 Hours Back Per Activation: What WCG’s New Tool Reveals About the Real Cost of Manual Study Startup
WCG's Activation Intelligence saves 20+ hours per study activation. Here's what that number means for site startup budgets and...
Proteomic Aging Clocks Enter Clinical Trials: What Sponsors Need to Know Before the FDA Does
Proteomic aging clocks are moving into clinical trials, but FDA surrogate endpoint standards and assay reproducibility gaps could stall...
Phase IV heart failure studies use digital tools to address patient dropout from low perceived benefit
Heart failure Phase IV studies use digital tools and remote monitoring to reduce patient dropout when perceived personal benefit...
CRIO Launches AI eSource Builder to Cut Protocol Review Time by Four Hours
CRIO's AI eSource Builder automates protocol-to-eCRF conversion, reducing eSource build time by four hours per study while enforcing consistent...
Senti Biosciences Adjourns Merger Vote, Seeking Additional Stockholder Support
Senti Biosciences adjourns merger vote seeking additional stockholder support to advance SENTI-202 spinout and gene-circuit platform.
Phio Pharmaceuticals Completes Commercial cGMP Batch of PH-762
Phio Pharmaceuticals completes commercial cGMP batch of PH-762, clearing a manufacturing prerequisite for its Phase 2b trial start planned...
ArriVent doses first patient with ARR-002 dual-target ADC for ovarian cancer
ArriVent doses first patient with ARR-002, a tetravalent antibody-drug conjugate targeting MUC16 and NaPi2b in ovarian cancer.
Zenas BioPharma releases Phase 3 obexelimab data in IgG4-related disease
Zenas BioPharma releases Phase 3 obexelimab IgG4-related disease data with open-label extension results showing durability against competitor inebilizumab.